Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant *Klebsiella pneumoniae*

Miranda E. Pitt, Alysha G. Elliott, Minh Duc Cao, Devika Ganesamoorthy, Ilias Kariaiskos, Helen Giamarellou, Cely S. Abboud, Mark A. T. Blaskovich, Matthew A. Cooper, *and* Lachlan J. M. Coin

**Abstract**
Extensively drug-resistant *Klebsiella pneumoniae* (XDR-KP) infections cause high mortality and are disseminating globally. Identifying the genetic basis underpinning resistance allows for rapid diagnosis and treatment. XDR isolates sourced from Greece and Brazil, including 19 polymyxin-resistant and five polymyxin-susceptible strains, were subjected to whole genome sequencing. Seventeen of the 19 polymyxin-resistant isolates harboured variations upstream or within *mgrB*. The most common mutation identified was an insertion at nucleotide position 75 in *mgrB* via an IS*Kpn26*-like element in the ST258 lineage and IS*Kpn13* in one ST11 isolate. Three strains acquired an IS1 element upstream of *mgrB* and another strain had an IS*Kpn25* insertion at 133 bp. Other isolates had truncations (C28STOP, Q30STOP) or a missense mutation (D29E) affecting *mgrB*. Complementation assays revealed all *mgrB* perturbations contributed to resistance. Missense mutations in *phoQ* (T281M, G385C) were also found to facilitate resistance. Several variants in *phoPQ* co-segregating with the IS*Kpn26*-like insertion were identified as potential partial suppressor mutations. Three ST258 samples were found to contain subpopulations with different resistance-conferring mutations, including the IS*Kpn26*-like insertion colonizing with a novel mutation in *pmrB* (P158R), both confirmed via complementation assays. These findings highlight the broad spectrum of chromosomal modifications which can facilitate and regulate resistance against polymyxins in *K. pneumoniae*.

**DATA SUMMARY**
Whole genome sequencing of the 24 clinical isolates has been deposited under BioProject PRJNA307517 (www.ncbi.nlm.nih.gov/bioproject/PRJNA307517).

**INTRODUCTION**
*Klebsiella pneumoniae* (KP) strains classified as extensively drug-resistant (XDR) are rapidly emerging due to the dissemination of plasmid-encoded resistance towards aminoglycosides, β-lactams, fluoroquinolones and carbapenems [1]. Notably, carbapenem-resistant KP have been linked to high morbidity and an overall mortality of 48 % in infected patients [2]. Polymyxin B and colistin (polymyxin E) are now one of the last viable therapeutic options [3]. Unfortunately, resistance to this last-line antibiotic class is an increasing global burden, with countries particularly impacted including Asia (South Korea [4, 5], India [6, 7]), Europe (Greece [8–10]), Italy [10, 11]) and Latin America (Brazil [12, 13]). Mortality is influenced by polymyxin resistance typically occurring on a multidrug-resistant (MDR) or XDR background; nephrotoxicity leads to suboptimal dosing as well as inadequacies in detection of heteroresistance [10, 14]. As a result, there is considerable uncertainty regarding the mortality associated with polymyxin-resistant infections. Combining several clinical cohorts has provided overall mortality estimates ranging from 20 to 100 % [10].

Polymyxins infiltrate Gram-negative bacteria via initial binding to the basal component of lipopolysaccharide, lipid A. This causes the displacement of Mg$^{2+}$ and Ca$^{2+}$, disrupting the outer and inner membrane integrity, resulting in
leakage of cytoplasmic contents and subsequent cell death, but the exact mechanism involved remains elusive [15, 16]. Inhibition of an intracellular target, the type II NADH-quinolone oxidoreductases, embedded in the inner membrane has also been identified [17]. An exposure in KP leads to the emergence of polymyxin resistance by triggering the activation of the two-component regulatory systems, PmrAB and PhoPQ [18–20]. These systems regulate a pathway that modulates pmrC and the pmrHFIJKLM operon, facilitating the addition of phosphoethanolamine (pEtN) and/or 4-amino-4-deoxy-1-arabinose to lipid A phosphate groups, resulting in impaired polymyxin binding interactions [21–23]. Disruption of mgrB, the negative regulator of PhoPQ, has been commonly observed in isolates of clinical origin [8, 24]. The constitutive up-regulation of pmrC and the pmrHFIJKLM operon incurs a minimal fitness cost and appears to be stable, with few reports of reversions [25, 26]. Heteroresistant populations, in which only a subset of bacteria are resistant in a phenotypically susceptible sample, have been reported in KP, which complicates diagnosis [27]. The emergence of pandrug-resistant KP is of grave concern [28] and this acquisition of resistance is further exacerbated by the recently reported plasmid-encoded colistin resistance gene mcr-1, which encodes a pEtN transferase enzyme [29, 30]. The presence of mcr genes in KP is currently a rarity with only a few reports of mcr-1, -1.2 and -3 [31–33]. Göttig et al. recently established a fitness cost associated with KP harbouring mcr-1, in contrast to Escherichia coli, which may explain the lack of isolates acquiring this gene [34]. This study aimed to investigate XDR-KP clinical isolates arising in Greece and Brazil during 2012–2014 to identify and validate genetic variants contributing to resistance. These variants were compared to prior clinical isolates to ascertain if these mutations have been previously detected globally.

METHODS

Bacterial isolates

Polymyxin-resistant XDR-KP clinical isolates were acquired from the Hygeia General Hospital, Athens, Greece, and Instituto Dante Pazzanese de Cardiologia, Brazil, from patients in 2012–2014. These isolates were sampled at random (non-sequential). We also obtained five polymyxin-susceptible strains which were utilized as a genomic background reference and a negative control for complementation assays. Cultures were supplied as stabs/slants or on agar, and were subsequently cultured in nutrient broth. Cultures were made to 20% (v/v) glycerol and stored at −80 °C. When required for assay or extraction, glycerol stocks were struck out to obtain single colonies on either nutrient agar or tryptic soy agar with 5% defibrinated sheep blood. Reference strains included E. coli (ATCC 25922) and Klebsiella spp. (ATCC 13883, ATCC 700603, ATCC BAA-2146), which were obtained from the American Type Culture Collection (ATCC).

Antimicrobial susceptibility assays

Species identification and susceptibility profiles of clinical isolates from Greece and Brazil were evaluated in the clinic using the VITEK2 system (bioMérieux). Strains were further validated at the Institute for Molecular Bioscience (IMB) (The University of Queensland, Australia) using the standard Clinical and Laboratory Standards Institute (CLSI) approved broth microdilution (BMD) methods with cation-adjusted Mueller-Hinton broth (caMHB). Resistance was determined as per CLSI guidelines [35] except for tigecycline and fosfomycin for which The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (Version 7.1, 2017) (see http://www.eucast.org) guidelines were implemented. Classification of isolates as MDR or XDR was determined through guidelines previously outlined [36].

DNA extraction

Isolates selected for sequencing exhibited a polymyxin-resistant XDR profile with five polymyxin-susceptible strains included to discern the mutations in mgrB, pmrAB and phoPQ segregating with susceptible isolates. DNA was extracted from overnight cultures using the DNeasy Blood and Tissue Kit (Qiagen) with the additional enzymatic lysis buffer pre-treatment as per the manufacturer’s instructions.
DNA was quantified with Qubit3.0 (ThermoFisher Scientific).

**DNA library preparation and sequencing**

Library preparation was performed using the Nextera XT kit (Illumina) with 1 ng input of DNA as per the manufacturer’s instructions. Quality of libraries was checked using a 2100 Bioanalyzer (Agilent Technologies). Libraries were prepared using the 2×300 v3 MiSeq kit and sequenced on an Illumina MiSeq with 300 bp paired-end sequencing reads and >100× coverage per sample.

**Sequencing analysis**

Paired-end reads were trimmed with Trimmomatic [37] and assembled using SPAdes [38]. The Rapid Annotation using Subsystem Technology (RAST) was utilized to annotate assembled genomes [39]. Assemblies were also uploaded to the Centre for Genomic Epidemiology (CGE) to identify sequence types (STs) (MultiLocus Sequence Typing Server 1.8 [40]) and acquired antibiotic resistance genes (ResFinder 3.0 [41]). A neighbour-joining tree was reconstructed using the 2358 *Klebsiella pneumoniae/quasipneumoniae/varicola* genes known to form the core genome multi-locus sequence type (cgMLST) using Ridom SeqSphere +v4.0.1 software [42]. Complete assemblies of publicly available reference genomes were obtained from www.ncbi.nlm.nih.gov/genome/?term=klebsiella. ST references included HS11286 (ST11), MS6671 (ST147), and NJST258.1 and NJST258.2 (ST258). Species references were *K. quasipneumoniae* (ATCC 700603, HKUOPA4) and *K. varicola* (At-22, GJ1).

**Variant detection**

Variants both in and flanking the genes *pmrAB*, *phoPQ* and *mgrB* were examined and sequence reads of all strains were aligned to the assembly of 20_GR_12, a polymyxin-susceptible type (cgMLST) using Ridom SeqSphere + v4.0.1 software [42]. Complete assemblies of publicly available reference genomes were obtained from www.ncbi.nlm.nih.gov/genome/?term=klebsiella. ST references included HS11286 (ST11), MS6671 (ST147), and NJST258.1 and NJST258.2 (ST258). Species references were *K. quasipneumoniae* (ATCC 700603, HKUOPA4) and *K. varicola* (At-22, GJ1).

**Insertion sequence element validation**

ISFinder [47] was used for the identification of insertion sequence (IS) elements. To confirm disruptive IS elements, *mgrB* was amplified with the primers displayed in Table S1 (available in the online version of this article) via 2× Phusion HF master mix (Invitrogen) under the following cycling conditions: 98°C for 10 s, 50°C for 30 s and 72°C for 60 s (35×). Amplicon identity was validated via Sanger sequencing.

**Complementation assays**

The contribution of variants to resistance was validated through complementation assays as previously described [48]. Briefly, genes (Table S1) were amplified from a polymyxin-susceptible isolate, 20_GR_12, and cloned into the pCR-Blunt II-TOPO vector via the Zero Blunt TOPO PCR cloning kit (Invitrogen). Chemically competent *E. coli* TOP10 cells were transformed and selected by the addition of 50 mg l\(^{-1}\) kanamycin in Mueller-Hinton agar (MHA). Isolation of plasmids was done via the PureLink Quick Plasmid Miniprep Kit (Invitrogen). The methodology for preparing electrocompetent cells and complementation assays was kindly provided by Dr Aurélie Jayol and Professor Patrick Nordmann. Briefly, overnight cultures were subcultured into 200 ml Luria-Bertani broth (1 : 100 dilution) and grown to an OD\(_{600}\) of 0.6±0.05. Cells were chilled on ice before centrifugation (10 000 r.p.m., 10 min, 4°C), washed twice with ice cold 10% glycerol and concentrated to 500 µl. KP isolates were transformed via electroporation (25 µF, 200 Ω, 1.25 kV cm\(^{-1}\)) with a Gene Pulser (Bio-Rad Laboratories). Selection was accomplished through supplementation of ≥500 mg l\(^{-1}\) kanamycin on MHA plates. Transformed colonies (n≥2) were acquired and placed in MHB containing 1500 mg l\(^{-1}\) kanamycin and 1 mM isopropyl β-D-1-thiogalactopyranoside (Sigma Aldrich). If polymyxin susceptibility was not restored upon complementation, genes harbouring mutations were further amplified and introduced into 20_GR_12. To discern the impact of additional mutations in *phoPQ* and *pmrB* segregating with disrupted *mgrB*, mutant genes were introduced into a polymyxin-resistant isolate only harbouring an IS element *mgrB* disruption, 7_GR_13. Controls included transformation of wild-type (WT) genes into 20_GR_12, sequencing of amplicons prior to introduction in the vector and in KP-transformed strains undergoing a plasmid extraction, and further PCR of the multiple cloning site. Antimicrobial testing against colistin and polymyxin B were conducted as described above.

**RESULTS**

**Characterization of clinical isolates**

KP isolates were all characterized in the hospital microbiology facility using VITEK2 cards. Several discrepancies were detected between VITEK2 and broth microdilution (BMD) results (Tables 1 and S2), predominantly the level of resistance towards aminoglycosides, tetracyclines, fosfomycin and tigecycline. A major dissimilarity was polymyxin susceptibility in 6_GR_12 (sensitive in BMD, resistant in VITEK2) and resistance in 23_GR_13 (resistant in BMD, sensitive in VITEK2). Polymyxin resistance was identified in 19 of the isolates and minimum inhibitory concentrations (MICs) ranged from 8 to >64 mg l\(^{-1}\). An abundance of
acquired resistance genes (Table 2) was detected and this presence corresponded to the antimicrobial testing phenotype. This analysis did not identify mcr genes (mcr-1, -2, -3, -4, -5) in these strains. Only 18_GR_14 and 19_GR_14 were not identified as extended-spectrum beta-lactamase producers amongst the polymyxin-resistant strains. Consequently, all polymyxin-resistant strains that harboured non-susceptibility to at least one antibiotic in 15 or more of the 17 antimicrobial categories were defined as XDR.

**Sequence type determination**

Sixteen of the 22 Greek clinical strains were found to belong to ST258 and the remaining were ST11, ST147 or ST383 (Table 1). While 5_GR_13 and 6_GR_12 were both ST383, only 5_GR_13 was resistant to polymyxin. Among the two strains from Brazil, 11_BR_13 was ST437 and 12_BR_13 was ST11. Strain 21_GR_13 had a profile previously undefined and has been newly designated ST2401. Further cgMLST studies were conducted on the isolates using complete assemblies of reference genomes for ST11 (HS11286), ST147 (MS6671), ST258 (NJST258_1, NJST258_2), K. quasipneumoniae (KQ) (ATCC 700603, HKUOPA4) and K. variicola (KV) (At-22, GJ1) (Fig. 1). For the ST258 isolates, these were more similar to NJST258_2 than to NJST258_1. Within this cluster, 7_GR_13, 9_GR_12 and 24_GR_13 were closely related (<15 allelic changes). Similarly grouped together were 2_GR_12 and 23_GR_12; 3_GR_13 and 22_GR_12; 13_GR_14 and 14_GR_14; and 18_GR_14 and 19_GR_14. In ST11, 16_GR_13 and 17_GR_14 harboured only three allele differences and the Brazilian isolate, 12_BR_13, had 206 variants apparent. ST383 isolates 5_GR_13 and 6_GR_12 only exhibited one allele change. ST147 1_GR_13 was not clonal to the previous pandrug-resistant KP, MS6671. Clustering analysis revealed 21_GR_13 as KQ rather than KV.

**MgrB disruption**

Seventeen of the 19 polymyxin-resistant strains exhibited either missense mutations, nonsense mutations or IS elements in mgrB (Table 2). Both 5_GR_13 and 19_GR_14 harboured a truncation while an amino acid change, D29E, was apparent in 3_GR_13. IS element disruptions in mgrB were present in 14 strains and in nine isolates, and an IS5-like element was integrated at nucleotide position 75 (Fig. S1). Sanger sequencing revealed this element was closely related to ISKpn26, herein known as ISKpn26-like, except for 12 BR_13 which matched ISKpn13. ISIR was detected upstream of mgrB in 11_BR_13 and an ISIR-like (A>C, 393 bp; C>T, 396 bp) element in 16_GR_13 and 17_GR_14. Strain 15_GR_13 had a deletion of the mgrB locus from nucleotide position 133 onwards. The 127 bp flanking region mapped to ISKpn25 with the transposase in the same orientation as mgrB. All three of the IS1 element insertions, but only one of the eight ISKpn26-like element insertions had the transposase in the same orientation as mgrB.

**Single, multiple and heterogeneous mutations**

Mutations in genes commonly identified to confer polymyxin resistance in KP include mgrB, phoPQ and pmrAB (Table 2). Several non-synonymous mutations were identified across the isolates (Table S3). These mutations were analysed through the prediction tool, PROVEAN, and were all identified to be deleterious, although this does not negate a functional purpose for these variants. ST383 contained several mutations in pmrAB although only Q30STOP in polymyxin-resistant 5_GR_13 was predicted to have an impact. Similarly, neutral changes in all four of these genes were detected in polymyxin-susceptible KQ strains ATCC 700603 and 21_GR_13. Strains 8_GR_13 and 9_GR_12 harboured a single detrimental missense mutation in phoQ. Seven of the 17 isolates containing an mgrB variant were accompanied by one or more missense mutations in phoPQ and/or pmrB. Predicted deleterious variants segregating with disrupted mgrB included pmrB (T140P, P158R), phoP (P74L, A95S) and phoQ (N253T, V446G), which were commonly found in the ST258 lineage. V446G (phoQ) and P158R (pmrB) were heterogeneous in 13_GR_14 [mutation allele frequency of 65% (V446G) and 66% (P158R)] and 14_GR_14 [mutation allele frequency of 52% (V446G) and 57% (P158R)]. Assembly revealed 23_GR_12 harboured an ISKpn26-like disrupted mgrB alongside the intact version with mutations in phoP and phoQ in 57% of the samples. Furthermore, assemblies for mgrB, pmrAB and phoPQ were aligned to ATCC 700603 (Table S4). Several non-synonymous mutations were detected, but the majority were not predicted to be deleterious. Various mutations were unique to KP compared to KQ. ST11, 147, 258 and 437 remained conserved across these genes with the exception of mutations predicted to be deleterious. ST383 harboured several dissimilarities including the lack of pmrA (D131N) and pmrB (S105N) and gain of pmrA (G144D, D149E) and pmrB (A5V, M175V). Only subtle differences were observed in KQ isolate 21_GR_13, which included pmrA (I220N, D221E) and pmrB (G358A). Predicted deleterious mutations detected both in polymyxin-susceptible and in polymyxin-resistant isolates included pmrA (Q140L) and pmrB (R256G).

**Role of mgrB disruptions and presence of heterogeneity via complementation assays**

Complementation of the WT gene elucidated the role of these mutations in resistance (Fig. 2). MICs were determined against polymyxin B and colistin, but no difference was observed. Introduction of pTOPO-mgrB restored susceptibility in all resistant isolates with mgrB coding mutations or upstream disruptions, with the exception of two strains heterogeneous for the mgrB disruption and a pmrB coding mutation (13_GR_14 and 14_GR_14) (Fig. 2a). For these two strains, pTOPO-mgrB restored susceptibility in none of three 13_GR_14 colonies and one of three 14_GR_14 colonies. Transformation of one out of three colonies for both 13_GR_14 and 14_GR_14 strains with pTOPO-pmrB restored susceptibility (Fig. 2d) and
<table>
<thead>
<tr>
<th>Strain*</th>
<th>Source†</th>
<th>Resistance profile‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AMK</td>
</tr>
<tr>
<td>1_GR_13</td>
<td>St</td>
<td>R</td>
</tr>
<tr>
<td>2_GR_12</td>
<td>U</td>
<td>R</td>
</tr>
<tr>
<td>3_GR_13</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>4_GR_12</td>
<td>B</td>
<td>R</td>
</tr>
<tr>
<td>5_GR_13</td>
<td>St</td>
<td>S</td>
</tr>
<tr>
<td>6_GR_12</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>7_GR_13</td>
<td>St</td>
<td>R</td>
</tr>
<tr>
<td>8_GR_13</td>
<td>St</td>
<td>R</td>
</tr>
<tr>
<td>9_GR_12</td>
<td>Br</td>
<td>I</td>
</tr>
<tr>
<td>10_GR_13</td>
<td>B</td>
<td>S</td>
</tr>
<tr>
<td>11_BR_13</td>
<td>U</td>
<td>S</td>
</tr>
<tr>
<td>12_BR_13</td>
<td>Br</td>
<td>S</td>
</tr>
<tr>
<td>13_GR_14</td>
<td>Br</td>
<td>I</td>
</tr>
<tr>
<td>14_GR_14</td>
<td>U</td>
<td>I</td>
</tr>
<tr>
<td>15_GR_13</td>
<td>St</td>
<td>I</td>
</tr>
<tr>
<td>16_GR_13</td>
<td>St</td>
<td>R</td>
</tr>
<tr>
<td>17_GR_13</td>
<td>St</td>
<td>R</td>
</tr>
<tr>
<td>18_GR_14</td>
<td>St</td>
<td>I</td>
</tr>
<tr>
<td>19_GR_14</td>
<td>St</td>
<td>I</td>
</tr>
<tr>
<td>20_GR_12</td>
<td>St</td>
<td>R</td>
</tr>
<tr>
<td>21_GR_13</td>
<td>U</td>
<td>S</td>
</tr>
<tr>
<td>22_GR_12</td>
<td>S</td>
<td>I</td>
</tr>
<tr>
<td>23_GR_12</td>
<td>St</td>
<td>R</td>
</tr>
<tr>
<td>24_GR_13</td>
<td>St</td>
<td>I</td>
</tr>
</tbody>
</table>

*Strain identification: numerical order catalogued at IMB_Country (GR, Greece; BR, Brazil) last two digits of isolation year.
†Source represented as B, blood; Br, bronchial secretion; U, urine; S, sputum; St, stool.
‡Antibiotic resistance as determined by BMD according to CLSI guidelines [EUCAST for fosfomycin (disc diffusion) and tigecycline] and in superscript, any discrepancies identified in VITEK2 results.

Antibiotic classes tested include: 1, aminoglycosides (amikacin, AMK; gentamicin, GEN; tobramycin, TOB); 2, anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporins (ceftaroline, CPT); 3, anti-pseudomonal penicillins + beta-lactamase inhibitors (piperacillin-tazobactam, TZP); 4, carbapenems (imipenem, IPM; meropenem, MEM); 5, non-extended spectrum cephalosporins (1st and 2nd generation) (cefazolin, CFZ); 6, extended-spectrum cephalosporins (3rd and 4th generation) (cefepime, FEP; ceftazidime, CTX; ceftriaxone, CAZ); 7, cephamycins (cefoxitin, FOO); 8, fluoroquinolones (ciprofloxacin, CIP); 9, folate pathway inhibitors (trimethoprim-sulfamethoxazole, SXT); 10, glycolcyclines (tigecycline, TGC); 11, monobactams (aztreonam, ATM); 12, penicillins (ampicillin, AMP); 13, penicillins + beta-lactamase inhibitors (ampicillin-sulbactam, SAM); 14, phenicols (chloramphenicol, CHL); 15, phosphonic acids (fosfomycin, FOP); 16, polymyxins (colistin, CST); 17, tetracyclines (minocycline, MIN; tetracycline, TET); R, resistant; I, intermediate; S, susceptible; N, not tested.
mgrB amplification of these colonies revealed an intact mgrB locus (Fig. S2). Colonies which were reverted on complementation were further passaged three times with no antibiotic pressure in order to remove the plasmid and discern if these mutations were contributing to resistance. After passaging, pTOPO-mgrB isolates harboured an MIC of 64 mg l\(^{-1}\), whilst pTOPO-pmrB colonies had an MIC of 16 mg l\(^{-1}\), confirming two resistant populations in these samples. 23 GR\_12 was also observed to have a heterogeneous mgrB disruption but did not carry a corresponding pmrB mutation, although it harboured similar mutations to 2 GR\_12 in phoPQ. Amplification of mgrB identified two of three 23 GR\_12 transformed colonies contained the IS element disruption and reverted to being susceptible upon complementation with pTOPO-mgrB.

Validation of resistance-conferring mutations in phoQ

Strains 8 GR\_13 and 9 GR\_12 harboured a single mutation in phoQ potentially conferring resistance (Table 2). When these isolates were transformed with pTOPO-phoQ, results remained variable where a lack of growth was present in a susceptible range (MIC ≤ 2 mg l\(^{-1}\)), although several wells containing high polymyxin B concentrations exhibited growth (Fig. 2c). This result was reproducible (n≥4) and therefore the mutated gene was introduced into a polymyxin-susceptible isolate, 20 GR\_12 (Fig. 2e). This complementation resulted in a consistent polymyxin-resistant phenotype.

Potential suppressor mutations in phoPQ

Several mutations co-segregating with the IS element-disrupted mgrB were detected, including phoP (P74L, A95S), phoQ (N253T, V446G) and pmrB (T140P). Complementation of WT genes in these isolates facilitated a 2-fold increase in MIC with the exception of 10 GR\_13, which had an additional predicted neutral mutation in phoQ (A225T) (Table S3, Fig. 2b–d). To evaluate the potential influence of these mutations on polymyxin resistance, mutated genes were introduced into a strain only containing the mgrB IS element disruption, 7 GR\_13 (Fig. 2f). Complementation of mutant pmrB (T140P) into 7 GR\_13 did not lead to an observable corresponding reduction in MIC, but once transformed into 20 GR\_12, a twofold increase in MIC was apparent (Fig. 2e). Variants in phoQ (N253T and V446G) exhibited a twofold reduction in MIC (Fig. 2e). Initially, the phoQ (V446G) mutation was anticipated to segregate with the mgrB-disrupted population in 13 GR\_14 and 14 GR\_14, but when phoQ was amplified from a colony reverted to susceptible via pTOPO-mgrB complementation, the WT phoQ was observed (Fig. S3). The phoQ (V446G) mutation was successfully amplified from a 14 GR\_14

Table 2. Potential mutations contributing to polymyxin resistance and acquired resistance genes

<table>
<thead>
<tr>
<th>Strain</th>
<th>MLST*</th>
<th>Predicted polymyxin resistance variants†</th>
<th>Acquired antibiotic resistance genes‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 GR_13</td>
<td>147</td>
<td>npm2 (NOS1), npm6, pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>2 GR_12</td>
<td>258</td>
<td>npm2 (NOS1), npm6, pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>3 GR_13</td>
<td>216</td>
<td>npm2 (NOS1), pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>4 GR_12</td>
<td>256</td>
<td>npm2 (NOS1), pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>5 GR_13</td>
<td>181</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>6 GR_12</td>
<td>393</td>
<td>-</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>7 GR_12</td>
<td>184</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>8 GR_12</td>
<td>163</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>9 GR_12</td>
<td>268</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>10 GR_13</td>
<td>306</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>11 GR_12</td>
<td>677</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>12 GR_12</td>
<td>411</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>13 GR_14</td>
<td>256</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>14 GR_14</td>
<td>159</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>15 GR_13</td>
<td>316</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>16 GR_12</td>
<td>239</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>17 GR_12</td>
<td>248</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>18 GR_12</td>
<td>256</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>19 GR_12</td>
<td>258</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>20 GR_12</td>
<td>258</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>21 GR_12</td>
<td>248</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>22 GR_12</td>
<td>258</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
<tr>
<td>23 GR_12</td>
<td>258</td>
<td>pmrB (T140P)</td>
<td>A, B, F, M, Q, S, Tr</td>
</tr>
</tbody>
</table>

*Multilocus sequence type as identified through MultiLocus Sequence Typing Server 1.8.
†Variations detected in mgrB, phoPQ and pmrAB potentially causing polymyxin resistance. Significant non-synonymous changes determined by PROVEAN analysis. WT (wild-type) alleles in comparison to 20 GR\_12. Displayed as gene impacted, initial amino acid, position and new amino acid. If a dash (–) is shown in front of the position, variant is encoded upstream and if a dash (–) is only displayed, no significant non-synonymous changes were detected in these loci. Insertion sequences (underlined) classified as A, identity as per ISFinder and orientation in superscript. Orientation determined as forward, if transposase is in the same direction as mgrB and conversely, reverse, if in the opposite direction to mgrB.
‡Acquired antibiotic resistance genes detected via ResFinder 3.0. Classes of antibiotics impacted are displayed as: A, aminoglycoside; B, beta-lactam; F, fosfomycin; M, macrolide; P, phenicol; Q, quinolone; R, rifampicin; S, sulphonamide; T, tetracycline; Tr, trimethoprim. Shading indicates detection of a gene (≥90 % homology, ≥60 % sequence length).
colony containing the pmrB (T158R) mutation. Although this mutation did not segregate with disrupted mgrB, it may act as a partial suppressor mutation when a resistance-conferring mutation is present in pmrB. Interestingly, a >4-fold reduction in MIC was witnessed for phoP mutations P47L and A95S, indicating partial suppressor mutations (Fig. 2e).

**DISCUSSION**

Polymyxin resistance in XDR-KP is of grave concern given that this is a last-line antibiotic, and resistance is increasingly prevalent in countries such as Greece and Brazil [10, 12–14, 49]. We evaluated the genetic basis of polymyxin resistance in a series of Greek and Brazilian clinical isolates from patients in 2012–2014 and found variants in genes mgrB, phoPQ and pmrAB. Causative mutations attributed to polymyxin resistance were identified in these loci, but the contribution of other genes warrants further investigation.

Inactivation of mgrB was highly prevalent in these strains with an ISKpn26-like element being the predominant cause of resistance, as confirmed by complementation restoring susceptibility in all isolates. Several other studies have observed an IS5-like element integration in the same position, including reports from Greece, Italy, France, Turkey and Colombia [8, 9, 50, 51]. The ISKpn26-like element resembled the same sequence from Greek isolates previously described [51]. We identified that this mutation still persisted in 2014, after being first detected in 2012 [9]. Disruptions in mgrB including the ISKpn26-like forward insertion

---

**Fig. 1.** Neighbour-joining tree of core genome MLST of 24 *Klebsiella* clinical isolates. Clustering of STs is indicated at the base of diverging branches. ST# indicates an uncharacterized MLST according to MLST server 1.8. cgMLST was used to compare completed assemblies including HS11286 (ST11), MS6671 (ST147), and NJST258_1 and NJST258_2 (ST258). Assemblies were also compared against *K. quasipneumoniae* (ATCC 700603, HKUOPA4) and *K. variicola* (At-22, GJ1) genomes.
Fig. 2. Complementation assays and influence of gene on polymyxin resistance. Polymyxin B MICs measured before (○) and after (■) complementation of the wild-type gene (a) pTOPO-mgrB, (b) pTOPO-phoP, (c) pTOPO-phoQ or (d) pTOPO-pmrB in the indicated resistant isolates. (e) Mutated genes complemented into 20_GR_12 (polymyxin-susceptible isolate) to determine if the variant induces polymyxin resistance. (f) Complementation of 7_GR_13 (IS element disrupted mgrB control) to detect potential suppressor mutations. Strains shown on the x-axis for (a)–(d) and superscript indicates variants in genes including mgrB (a), phoP (b), phoQ (c) and pmrB (d) that differ from 20_GR_12. For (e) and (f), the x-axis shows the gene complemented with amino acid variation in parentheses. The dotted line at 2mg l⁻¹ represents the breakpoint for polymyxin B. Values are mean±sd, where no error bar indicates no fluctuation in MIC (n≥2 colonies).
at nucleotide 75 in ST147, ISKpn13 integration at nucleotide 75 in ST11 and ISKpn25 in the ST258 lineage have yet to be reported. We identified ISIR or ISIR-like elements positioned upstream of mgrB in three isolates (11_BR_13, 16_GR_13, 17_GR_14) which were reverted upon complementation indicating an impact on the promoter region.

Truncations identified at positions 28 and 30 of mgrB have been previously detected, although these were identified in differing STs, indicating mutations potentially have arisen independently in Greece [24, 52]. Complementation restored susceptibility to polymyxins for these mutations and this study further revealed the amino acid change D29E in 3_GR_13 to be a resistance-conferring mutation. These findings support the notion that intact MgrB is required to confer negative feedback on PhoPQ [8]. The inactivation of mgrB is prevalent in polymyxin-resistant KP and may arise owing to its capacity to promote virulence and further attenuate the early host defence response, with little or no fitness cost [53].

Single predicted detrimental mutations were observed in the phoQ histidine kinase region, critical for phosphorylation and interaction with phoP, in 8_GR_13 (G385C) and 9_GR_12 (T281M). The G385C mutation had previously been reported, [24], but in a different ST. Complementation revealed an inconsistent MIC for these strains, although when a polymyxin-susceptible isolate was transformed with the mutated gene, full resistance was restored. Dominance of mutated phoQ has recently been highlighted and these results may imply the inability of pTOPO-phoQ to override the resistance caused by these mutations [54]. Furthermore, the inconsistencies in MIC may be attributed to the heightened expression of WT phoQ in the pCR-Blunt II-TOPO vector and warrants further investigation.

Several non-synonymous changes were identified to be not deleterious according to PROVEAN analysis. Notably, these were abundant in KQ strains, including 21_GR_13 and KP ST383 isolates. When these clinical isolates were aligned to ATCC 700603, multiple coding changes were identified, with the majority detected as neural changes with the exception of pmrA (Q140L) and pmrB (R256G). These mutations represent lineage-specific mutations, but this does not negate the possibility of previously resistance-conferring variants being acquired in these loci with subsequent rever- sion mutations to give rise to a susceptible phenotype.

Heterogeneity was apparent in several isolates. In near equal ratios, 13_GR_14 and 14_GR_14 possessed the ISKpn26-like mgrB disruption and a new mutation conferring resistance in pmrB, P158R, as determined by complementation. 23_GR_12 contained approximately half the reads mapping to the undisrupted genes and the other to the ISKpn26-like strain, with several additional predicted deleterious mutations. This heterogeneity may explain the initial clinical detection for this isolate to be polymyxin-susceptible.

Several isolates harbouring ISKpn26-like element-disrupted mgrB were accompanied by mutations in phoPQ and/or pmrB. These changes were present in ≥98 % of reads, making the involvement of heterogeneity unlikely. Once complemented, an increase in resistance was commonly recorded. This potentially reflects partial suppressor mutations as strains which solely possessed this IS element disruption commonly exhibited a heightened MIC of ≥64 mg l⁻¹. One variant segregating with this disruption included pmrB T140P. This had formerly been identified in an ST258 lineage but even when the resistant gene was complemented, the MIC increased by twofold but was not defined as clinically resistant [24, 55].

When mutated phoP or phoQ were introduced into the mgrB-disrupted isolate, a reduction in MIC was apparent. The involvement of additional mutations in PhoPQ causing a suppressing effect on the level of resistance in a background where the disrupted mgrB is lacking has yet to be reported in KP. Previous research by Miller et al. [56] determined additional mutations in PhoPQ altered polymyxin resistance in Pseudomonas aeruginosa. Their study describes phoP mutations with the capacity to partially or fully suppress resistance-causing mutations in phoQ. These mutations in phoP were near or within the DNA binding site, which differs from our results, where the mutations are impacting the response regulatory region that interacts with PhoQ. Conversely, all mutations partially suppressing the MIC were identified to be targeting the HAMP (present in Histidine kinases, Adenylate cyclases, Methyl-accepting proteins and Phosphatases) domain and histidine kinase component of PhoQ. These were in regions similar to revertant P. aeruginosa strains identified by Lee and Ko [57]. We postulate these mutations are perturbing the critical transfer of phosphoryl groups from the histidine kinase of PhoQ to PhoP and subsequent pmrD expression. Whether these mutations constitute a fitness advantage due to the reduction of metabolism required for the production of lipopolysaccharide modifications is yet to be discerned. Furthermore, due to variability in some of the complementation data, a knockout phoPQ background and introduction of genes that are potential suppressor mutations is required.

Rapid and accurate detection of mutations attributed to polymyxin resistance remains a long-standing problem. Our research has contributed to the current understanding of the dissemination and evolution of this resistance in KP. Although our sample size is limited, this study highlights several issues arising from solely interrogating genomes for resistance detection, including ST-specific non-synonymous changes, and heterogeneity. Our study reveals several mutations causing polymyxin resistance across various STs in comparison with prior literature. These include the mgrB ISKpn26-like disruption (nucleotide 75), truncations in mgrB (nucleotides 28 and 30) and a missense mutation in phoQ (G385C). The study provides the first potential report of suppressor mutations for polymyxin resistance. Through complementation assays, we have discerned the role of these modifications and have identified resistance-causing
variants that can be monitored in future genome-based diagnostics.

Funding information
LC is an ARC Future Fellow (FT110100972). MAC is an NHMRC Principal Research Fellow (APP1095350) and currently holds a fractional Professorial Research Fellow appointment at the University of Queensland with his remaining time as CEO of Inflazome Ltd, a company headquartered in Dublin, Ireland, that is developing drugs to address clinical unmet needs in inflammatory disease by targeting the inflammasome. MEP is an Australian Postgraduate Award scholar. AGE and MATB are supported in part by a Wellcome Trust Strategic Award 104797/Z/14/Z. Research was supported by NHMRC grants (APP1005350, APP 1045326), an NIH grant (R21AI098731/R33AI098731) and an AID sequencing Grant (2013) as well as funding from the Institute for Molecular Bioscience Centre for Superbug Solutions (610246).

Acknowledgements
We thank Dr Aurélie Jayol and Professor Patrice Nordmann for providing their complementation assay methodology. The authors thank Maite Amado and Angela M. Kavanagh for technical support with susceptibility assays and M. Rhia L. Stone for the quality control of antibiotics. We acknowledge the sequencing services provided by the Australian Genome Research Facility. We thank the team of the curators of the Institut Pasteur MLST system (Paris, France) for importing novel alleles, profiles and/or isolates at http://bigsdb.web.pasteur.fr.

Conflicts of interest
The authors declare that there are no conflicts of interest.

Ethical statement
There is no human or animal work in this study.

Data bibliography
1. NCBI Bioproject PRJNA307517 (2016).

References


